Exscientia (EXAI) Details Pipeline Prioritisation Strategy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Exscientia Details Pipeline Prioritisation Strategy
October 3, 2023 8:00 AM EDTConcentrating rapidly emerging pipeline on most differentiated, highest value oncology targets, including CDK7 and LSD1 programmes
Partnering or discontinuing internal development of programmes outside of core focus, including A2A and select discovery targets
Strategy will support continued investment into market-leading technology while maintaining cash runway well into 2026
Partnered pipeline continues to progress with achievement of first milestone for Sanofi collaboration and new collaboration with Merck KGaA
OXFORD, U.K.--(BUSINESS WIRE)-- Exscientia plc (Nasdaq:... More



